WO2010027498A3 - Compositions and methods for inducing satiety and treating non-insulin dependent diabetes emillitus, pre-diabetic symptoms, insulin resistance and related disease states and conditions - Google Patents
Compositions and methods for inducing satiety and treating non-insulin dependent diabetes emillitus, pre-diabetic symptoms, insulin resistance and related disease states and conditions Download PDFInfo
- Publication number
- WO2010027498A3 WO2010027498A3 PCT/US2009/005016 US2009005016W WO2010027498A3 WO 2010027498 A3 WO2010027498 A3 WO 2010027498A3 US 2009005016 W US2009005016 W US 2009005016W WO 2010027498 A3 WO2010027498 A3 WO 2010027498A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- subject
- provides
- dosage form
- ileum
- dependent diabetes
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
Abstract
The invention provides methods of treatment that induce satiety in a subject for a period of at least around twenty- four hours by once-daily administration to the subject of a controlled release dosage form, wherein the dosage form is administered while the subject is in the fasted state and at a time of around six to around nine hours prior to the subject's next intended meal, and wherein the dosage form comprises a controlled release composition, which comprises an enterically-coated, ileum hormone-stimulating amount of a nutritional substance and releases the majority of the nutritional substance in vivo upon reaching the subject's ileum. The invention also provides a diagnostic tool for probing the health and disease state of the ileal hormones, excess or deficiencies. The invention provides a safe vehicle for targeted deliveries of chemical, pharmaceuticals, natural substances and nutrition to the ileum. The present invention also provides a method for treating noninsulin dependent diabetes mellitus, pre-diabetic symptoms, and insulin resistance, as well as a number of disease states and conditions including gastrointestinal disorders as otherwise described herein.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/932,633 US9757346B2 (en) | 2008-09-03 | 2011-03-02 | Compositions and methods for treating insulin resistance and non-insulin dependent diabetes mellitus (type II diabetes) |
US15/623,734 US20180369177A1 (en) | 2008-09-03 | 2017-06-15 | Compositions and methods for inducing satiety and treating non-insulin dependent diabetes mellitus, pre-diabetic symptoms, insulin resistance and related disease states and conditions |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US19081808P | 2008-09-03 | 2008-09-03 | |
US61/190,818 | 2008-09-03 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/932,633 Continuation-In-Part US9757346B2 (en) | 2008-09-03 | 2011-03-02 | Compositions and methods for treating insulin resistance and non-insulin dependent diabetes mellitus (type II diabetes) |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2010027498A2 WO2010027498A2 (en) | 2010-03-11 |
WO2010027498A3 true WO2010027498A3 (en) | 2010-06-03 |
Family
ID=41797725
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2009/005016 WO2010027498A2 (en) | 2008-09-03 | 2009-09-02 | Compositions and methods for inducing satiety and treating non-insulin dependent diabetes emillitus, pre-diabetic symptoms, insulin resistance and related disease states and conditions |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2010027498A2 (en) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8828953B2 (en) | 2009-04-20 | 2014-09-09 | NaZura BioHealth, Inc. | Chemosensory receptor ligand-based therapies |
US9901551B2 (en) | 2009-04-20 | 2018-02-27 | Ambra Bioscience Llc | Chemosensory receptor ligand-based therapies |
US8999721B2 (en) | 2009-10-23 | 2015-04-07 | Therabrake, Inc. | Method and system to provide personalized pharmaceutical compositions and dosages |
US20130273154A1 (en) * | 2011-03-02 | 2013-10-17 | Joseph M. Fayad | Oral formulations Mimetic of Roux-en-Y gastric bypass actions on the ileal brake; Compositions, Methods of Treatment, Diagnostics and Systems for treatment of metabolic syndrome manifestations including insulin resistance, fatty liver disease, hpperlipidemia, and type 2 diabetes |
US20190262367A1 (en) * | 2010-03-03 | 2019-08-29 | Volant Holdings Gmbh | Oral formulations mimetic of roux-en-y gastric bypass actions on the ileal brake; compositions, methods of treatment, diagnostics and systems for treatment of metabolic syndrome manifestations including insulin resistance, fatty liver disease, hyperlipidemia, and type 2 diabetes |
EP2407034A1 (en) * | 2010-07-17 | 2012-01-18 | Cognis IP Management GmbH | Particles |
BR112013009635A2 (en) * | 2010-10-19 | 2016-07-12 | Elcelyx Therapeutics Inc | chemosensory receptor ligand-based therapies |
KR20190060879A (en) | 2011-03-02 | 2019-06-03 | 제롬 쉔타그 | Compositions, methods of treatment and diagnostics for treatment of hepatic steatosis alone or in combination with a hepatitis c virus infection |
US20180099001A1 (en) | 2011-04-29 | 2018-04-12 | Volant Holdings Gmbh | Diagnostics and methods for treatment of non-alcoholic hepatic steatosis and hepatic steatohepatitis, and prevention of complications thereof |
CA3107450A1 (en) | 2012-03-29 | 2013-10-03 | Therabiome, Llc | Gastrointestinal site-specific oral vaccination formulations active on the ileum and appendix |
CA2897448A1 (en) * | 2013-01-08 | 2014-07-17 | Jerome Schentag | Activation of the endogenous ileal brake hormone pathway for organ regeneration and related compositions, methods of treatment, diagnostics, and regulatory systems |
MX2015011462A (en) | 2013-03-14 | 2016-05-31 | Jerome J Schentag | Cholestosome vesicles for incorporation of molecules into chylomicrons. |
US9907755B2 (en) | 2013-03-14 | 2018-03-06 | Therabiome, Llc | Targeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents |
CN112074197A (en) * | 2018-03-07 | 2020-12-11 | 安纳生物科技有限公司 | Compositions for type II diabetes and for providing sustained energy release over time |
WO2020120519A1 (en) | 2018-12-10 | 2020-06-18 | Aphaia Pharma Ag | Combinatorial oral treatment of metabolic disorders through orchestrated release of enterokines |
ES2906316T3 (en) | 2018-12-10 | 2022-04-18 | Aphaia Ip Ag | Pharmaceutical oral dosage forms for the treatment of metabolic disorders and related diseases through the orchestrated release of enterocins |
IL298948A (en) | 2020-06-10 | 2023-02-01 | Aphaia Ip Ag | Pharmaceutical compositions containing enterokine-releasing substances in multiple dosage forms in combination with gelling agents |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5322697A (en) * | 1992-05-28 | 1994-06-21 | Meyer James H | Composition and method for inducing satiety |
WO2000018377A1 (en) * | 1998-09-28 | 2000-04-06 | Warner-Lambert Company | Enteric and colonic delivery using hpmc capsules |
US20050244518A1 (en) * | 2000-06-12 | 2005-11-03 | Ruo Huang | Dietary supplement and related method |
-
2009
- 2009-09-02 WO PCT/US2009/005016 patent/WO2010027498A2/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5322697A (en) * | 1992-05-28 | 1994-06-21 | Meyer James H | Composition and method for inducing satiety |
WO2000018377A1 (en) * | 1998-09-28 | 2000-04-06 | Warner-Lambert Company | Enteric and colonic delivery using hpmc capsules |
US20050244518A1 (en) * | 2000-06-12 | 2005-11-03 | Ruo Huang | Dietary supplement and related method |
Non-Patent Citations (1)
Title |
---|
MELA, D. J.: "Novel food technologies: enhancing appetite control in liquid meal replacers", OBESITY, vol. 14, no. SUPP., July 2006 (2006-07-01), pages 179S - 181S * |
Also Published As
Publication number | Publication date |
---|---|
WO2010027498A2 (en) | 2010-03-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2010027498A3 (en) | Compositions and methods for inducing satiety and treating non-insulin dependent diabetes emillitus, pre-diabetic symptoms, insulin resistance and related disease states and conditions | |
Molina‐Molina et al. | Exercising the hepatobiliary‐gut axis. The impact of physical activity performance | |
WO2011094337A8 (en) | Glucagon antagonist - gip agonist conjugates and compositions for the treatment of metabolic disorders and obesity | |
EP3335710A3 (en) | Use of nutritional compositions for preventing disorders | |
EP2069768A4 (en) | Compositions and methods for diagnosis and treatment of type 2 diabetes | |
WO2008043033A3 (en) | Fibrillation-resistant insulin and insulin analogues | |
EP2201370A4 (en) | Compositions and methods for diagnosis and treatment of type 2 diabetes | |
CL2007003440A1 (en) | COMPOUNDS DERIVED FROM AZACICLOALCANOS, INHIBITORS FROM ESTEAROIL-COENZIMA TO DELTA-9 DESATURASA; PHARMACEUTICAL COMPOSITION; AND USE FOR THE TREATMENT OF DISEASES SUCH AS TYPE 2 DIABETES, INSULIN RESISTANCE, LIPID DISORDERS, OBESIDA | |
MX2009004801A (en) | Nicotinic acetylcholine receptorsub-type selective amides of diazabicycloalkanes. | |
WO2008036341A3 (en) | Compositions and methods relating to glucagon receptor antibodies | |
UA98962C2 (en) | Thyroid hormone analogues, pharmaceutical composition comprising thereof, method for the treatment using thereof, use thereof and preparation method | |
WO2008084504A3 (en) | Pharmaceutical compositions of angiotensin ii receptor blockers | |
WO2008030830A3 (en) | Sustained-release composition and method of use thereof | |
WO2007122635A3 (en) | Controlled release formulation comprising anti-epileptic drugs | |
BR0314619A (en) | Ghrh's analogs | |
EA201100565A1 (en) | COMPOSITIONS AND METHODS OF TREATMENT OF INTESTINAL DISEASES USING GRANULATED MESALAMINE | |
WO2011038014A3 (en) | Composition and method for treatment of diabetes | |
JP2016507500A (en) | Method for treating GI tract disorders | |
WO2006042002A3 (en) | Compositions and methods for treating disease | |
CN104884052A (en) | 4-hydroxy-2-methyl-5-(propan-2-ylidene)cyclohex-3-enecarbaldehyde for the prevention and treatment of a cognitive, neurodegenerative or neuronal disease | |
CN101171029A (en) | Agent for treating and/or preventing of neuropathic pain | |
CN101596244A (en) | A kind of medicine for external use for the treatment of rheumatism atrophic arthritis | |
RU2009144121A (en) | COMPOSITIONS (-) - E-10-OH-NT AND METHODS FOR THEIR SYNTHESIS AND USE | |
Nwobodo | Toxicity and safety concerns in orlistat therapy for obesity: A critical evaluation | |
JP2013500943A5 (en) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09811852 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORMS 1205A DATED 17.05.11 AND 02.08.11) |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 09811852 Country of ref document: EP Kind code of ref document: A2 |